The selection of appropriate cancer models is a key prerequisite for maximising translational potential and clinical relevance of in-vitro oncology studies. 
Introduction
The use of appropriate cancer in vitro models is one of the most important requirements for investigating cancer biology and for successfully developing new anticancer therapies. Much effort has been devoted to evaluating the extent of phenotypic and genotypic similarities between existing cancer models and the primary tumours they aim to represent (Ahmed et al., 2013; Beaufort et al., 2014; Ince et al., 2015; Medico et al., 2015; Qiu et al., 2016) . Despite inherent limitations, immortalised human cancer cell lines are the most commonly used experimental models in pre-clinical oncology research. Technological advancement in high-throughput 'omics' techniques and the availability of rich cancer genomics datasets, such as those provided by The Cancer Genome Atlas (TCGA, http://cancergenome.nih.gov), the International Cancer Genome Consortium (ICGC) (Zhang et al., 2011) , the NCI-60 panel (Shoemaker, 2006) , the Cancer Cell Line Encyclopedia (CCLE) (Barretina et al., 2012) , the Cell Model Passports (van der Meer et al., 2019) , the Genomics of Drug Sensitivity in Cancer (GDSC) (Garnett et al., 2012; Iorio et al., 2016) , the COSMIC Cell Line Project (Forbes et al., 2017) and many others, have transformed the way preclinical cancer models can be assessed and prioritised. To this end, analytical methods to evaluate the suitability of cell lines as tumour models have been proposed in recently published works (Domcke et al., 2013; Jiang et al., 2016; Mouradov et al., 2014; Sinha et al., 2017; Sun and Liu, 2015; Vincent et al., 2015; Zhao et al., 2017) . Although these studies provide useful guidelines for choosing appropriate (and avoiding poorly suited) cell line models, they are restricted to individual cancer types. Most importantly, they require expert knowledge of the genomic alterations known to have a specific functional role in the tumour (sub)type under consideration (Domcke et al., 2013; Jiang et al., 2016) , or in the opposite case, they consider all individual variants regardless of their clinical relevance or functional impact, weighting these solely based on their frequency in single-sample based metrics (Sinha et al., 2015) . As a consequence, there is a need for robust computational methods able to integrate the molecular characterisation of large cohorts of primary tumours from different tissues, extracting the most clinically relevant features in an unbiased way, and evaluating/selecting representative in vitro models on the basis of these features.
We have recently published a large molecular comparison of cancer cell lines and matched primary tumours at the population level . Our results show that cell lines recapitulate most of the oncogenic alterations identified in matched primary tumours, and at similar frequencies. Building on our previous work, here we present CELLector, a tool for genomics-guided selection of cancer in vitro models.
CELLector is based on an algorithm that combines methods from graph theory and market basket analysis (Han et al., 2011) . It makes use of large-scale tumour genomics data to explore and rank patient subtypes based on genomic signatures (e.g. combinations of genomic alterations) identified in an unsupervised way based on their prevalence.
Subsequently, it ranks cell line models based on their genomic resemblance to the identified patient subtypes. Additionally, CELLector enables the identification of disease subtypes currently lacking representative in vitro models, which could be prioritised for future development. Here we demonstrate clinical relevance and potential translational application of the patient-defined signatures uncovered by CELLector through systematic analyses associating the signatures to differential patient prognosis, and response to in vitro drug treatment.
CELLector is available as an open-source user-friendly R Shiny application at https://ot-cellector.shinyapps.io/cellector_app/ (code available at https://github.com/francescojm/CELLector_App ) and R package at https://github.com/francescojm/CELLector , it also provides interactive visualisations and intuitive explorations of results and underlying data.
Results

Overview of CELLector
CELLector is implemented into two distinct modules. The first module recursively identifies the most frequently occurring sets of molecular alterations (signatures) in a cohort of primary tumours (from TCGA or provided by the user), by focusing on a set of recently published or user-defined clinically relevant genomic features. In the default setting, these genomic features encompass somatic mutations in 470 high-confidence cancer driver genes and copy number gains/losses of 425 recurrently altered chromosomal segments, and were identified by applying state-of-art computational tools, such as the intOGen pipeline (Gonzalez-Perez et al., 2013; Gundem et al., 2010) and ADMIRE (van Dyk et al., 2013) , to the genomic characterisation of a cohort of 11,289 cancer patients (from the TCGA (http://cancergenome.nih.gov), the ICGC (Zhang et al., 2011) and other publicly available studies. Epigenomic data can also be used by including in the analysis the (discrete) methylation status of 378 informative CpG islands within gene promoters. These were identified in Iorio et al., 2016 based on the multimodal distribution of their methylation signal (indicative of the signal being informative and not tissue-specific) across primary tumour samples in at least one cancer type.
Based on the collective presence/absence of these alterations sets, CELLector partitions the primary tumours into distinct subpopulations prioritising them based on their prevalence in the patient population ( Figure 1A ). The second module determines the status of the identified molecular signatures (i.e. combinations of genomic alterations) in cancer cell lines (from user-defined or derived from Iorio et al., 2016 data) in order to identify the best-representative models for each patient subpopulation ( Figure 1B ). This approach unveils the extent of disease heterogeneity covered by representative models, and it also enables the identification of molecular signatures underlying tumour subtypes currently lacking representative models ( Figure 1C ).
By default, CELLector makes use of built-in datasets from the genomic characterisation of primary tumours and cell lines derived from 16 different tissues (Supplemental Information Table S1 and STAR Methods). In addition, CELLector can be used on user-defined/provided tumour and cell line genomic datasets, and sets of genomic features and individual genomic variants passing recurrence based filters (based on frequencies observed in COSMIC (Forbes et al., 2017) , or user defined ones). Finally, cell line annotations and genomic data can be optionally synchronised to the latest installment of the Cell Model Passports (van der Meer et al., 2019) , and an independent module (the CELLector Binary Event Matrix (BEM) builder module) allows creation of fully customisable genomic matrices using public or user-defined genomic data for both primary tumours and cell lines. A. Genomic features of primary tumours are used to identify recurrent subpopulations associating them with combination of genomics events (CELLector signatures). These are modeled and visualised hierarchically, by assembling the CELLector search space. B. The resulting CELLector search space is then used to map molecular similarities between the identified tumour subpopulations and cell line models. C. CELLector returns a list of cell line models that best represent the identified tumour subpopulations, thus maximising the coverage of disease heterogeneity, and highlighting tumour subtypes currently lacking representative in vitro models.
CELLector modules
In the first module, CELLector assembles a search space by segmenting cancer patients into a hierarchical structure visualised through a sunburst diagram. By mapping cell lines onto individual patient segments, this structure provides a prioritisation strategy for choosing the most representative models to be included in a new in vitro study. This strategy also ensures that the number of patients represented by at least one selected model, is maximised.
Particularly, CELLector recursively segments patients by grouping them according to the presence/absence of genomic alterations most frequently occurring in the patient cohort.
This also minimises the corresponding number of segments, and is performed by a greedy algorithm that proceeds as follows. Starting from an initial cohort of patients, the most frequent genomic alteration (or set of genomic alterations) is identified. This can be an individual mutation/copy-number-alteration/hypermethylated-gene-promoter, or a pair/triplet of such alterations occurring simultaneously. In the latter case these are identified by using the Eclat algorithm (Kaur, 2014) for the identification of frequent itemsets in commercial transaction databases. Based on this, the cohort of patients is split into two subpopulations depending on the presence/absence of the most frequent alteration identified (collective presence/absence if considering pairs/triplets of alterations). The obtained partition defines two subsets: the alteration(s) support set and its complement . The algorithm is then executed recursively on the two resulting subpopulations: to refine the support set ( refinement recursion ) and to analyse its complement ( complement recursion ), respectively.
The recursions continue until all the alteration sets with a support of minimal user-defined size are identified, and the corresponding patient segments are defined. The identified patient sub-populations and underlying signatures are stored in a hierarchical data object, which can be visualised as a sunburst and whose structure reflects the recursive calls of the algorithm ( Figure 2A ).
To facilitate mapping cell lines onto patient segments and their prioritisation, the search space building algorithm also stores intermediate and final results in a binary tree structure. Particularly, each genomic alteration (or alteration pair/triplet) identified recursively through the search space building algorithm is stored in a tree node. Linking nodes identified in adjacent recursions yields a binary tree, which provides an alternative way of visualising the CELLector search space , better reflecting its construction steps ( Figure 2A ). Visual representation of the CELLector search space constructed based on the prevalence of mutations in high-confidence cancer driver genes observed in cohort of BRAF mutant colorectal (COREAD) tumours (box 1 and box 2), and considering only microsatellite instable cell lines. Each path from the root of the binary three (at the top) to any of its nodes, corresponds to a segment (with the same colour) in the sunburst (at the bottom) and it represents a tumour subpopulation with an associated genomic signature (also reported in table B). The branches of the tree reflect the recursive steps of the algorithm with colored arrows specifying a recursion that aims at refining the analysis of the subpopulation corresponding to the source node (green) or at analysing its complementary subpopulation (orange). The prevalence of the identified signatures, and their hierarchical co-occurrence is represented by the length of the corresponding segment in the sunburst. B. Cell Line Map table including microsatellite instable cell lines mirroring the genomic signatures defining tumour subpopulations of the CELLector search space . The models in green represent a possible choice of 4 cell lines that could be selected in the presented case study.
This tree defines, by construction, logic formulas, one for each patient segment. In fact, each individual path (from the root to any node) of the tree corresponds to a segment in the sunburst visual (Figure 2A) , and it defines a rule (a logic formula, or signature). This is represented as a logic AND of multiple terms, one per each node in the path ( Figure 2B ).
These terms are negated (~) when the corresponding node is linked through the path to another node mapping alteration(s) identified in a complement recursion step rather than a refinement recursion step.
Per construction, if the genome of a given patient of the analysed cohort satisfies the rule associated to a given path in the tree, then that patient belongs to the segment associated with that path, or (for simplicity) to its terminal node. Similarly, cell lines are mapped onto patient segments. Collectively, all the paths in the search space provide a representation of the spectrum of molecular alterations (and their combinations) most frequently observed in a given cancer type, and their clinical prevalence in the analysed cohort of patients ( Figure 2A ).
The order of the nodes resulting from a visit of this tree detailed below, defines the priority of the corresponding mapped cell lines. This provides a possible choice of the best n cell lines, maximising the covered genomic heterogeneity of the considered cohort of cancer patients.
Once constructed, the CELLector search space is mined by a second module selecting the most representative set of cell lines maximising their covered genomic heterogeneity, via a guided visit of the search space tree (STAR Methods), thus also identifying tumour subtypes lacking representative cell line models ( Figure 2B ). Particularly, this visit starts from the centre of the search space sunburst considering the largest and innermost segment (corresponding to the genomic alteration -or set of alterations -most frequently occurring in the analysed cohort of patients), and proceeds through adjacent segments (from the 2nd largest one to the 3rd and so on). When all the segments in a given level have been visited and stored in a queue, the algorithm removes the first segment from the queue and the visit restarts considering its sub-segments in the outer level of the sunburst, from the largest one to the 2nd largest one and so on. The recursion continues until the queue is emptied. Each time a segment is visited for the first time, the algorithm picks one of the cell lines mapped on it. The resulting ordered list of cell lines is outputted as a possible optimal selection as it includes cell lines that are representative of the largest subset of patients ( Figure 2B ).
CELLector capabilities
CELLector can assist the selection of the best-representative preclinical models to be employed in molecular oncology studies. It also enables a frequency-based molecular subtyping/classification of any disease cohort. As detailed in the previous section, one of the approaches that users can pursue with CELLector is a simple guided visit of its search space to select the optimal set of n cell lines to be included in a small-scale in vitro study or a low-throughput screen. The selected cell lines are picked from those mapped to the first n nodes of the searching space, as they appear in the guided visit of the corresponding tree/sunburst and, per construction, this guarantees that the coverage of the genomic heterogeneity of a particular cancer type is maximised by the selected cell lines.
Another functionality of CELLector is the provision of a quantitative estimation of the quality of a given cell line in terms of its ability to represent the entire cohort of considered patients. This is quantified as a trade-off between two factors. The first factor is the length of the CELLector signatures (in terms of number of composing individual alterations) that are present in the cell line under consideration. This is proportional to the granularity of the representative ability of the cell line, i.e. the longest the signature the more precisely defined is the represented sub-cohort of patients. The second factor is the size of the patient subpopulation represented by the signatures that can be observed in the cell line under consideration, thus accounting for the prevalence of the sub-cohort modeled by that cell line.
In addition, given that the choice of appropriate in vitro models often depends on the context of the study, while constructing the search space users can restrict the analysis to a given sub-cohort of patients, by determining a priori based on the presence/absence of a given genomic feature. Matrix (BEM) builder, which can be also used to assemble and export genomic binary matrices (for both cell lines and primary tumours). These can be used within CELLector itself or by other tools, for instance to identify markers of drug responses or gene essentiality using publicly available data for example, from the Genomics of Drug Sensitivity in Cancer (GDSC) portal Yang et al., 2012 ; Garnett et al., 2012 ) or the Cancer Dependency Map web-sites Tsherniak et al., 2017) , and tools such as GDSCtools (Cokelaer et al., 2018) , among others.
Finally, the CELLector R Shiny app provides additional functionalities enabling an interactive exploration of the tumour/cell line genomic features and final results. A tutorial demonstrating all these functionalities, example case studies, and a step-by-step guide to reproduce the results reported in these case studies is provided as Supplemental Information.
Use Case: Selecting Microsatellite Instable Cell Lines Representing BRAF
Mutant Colorectal Cancers
In this section, we present a practical example to demonstrate the usefulness of
CELLector in an experimental study design. Detailed instructions on this and other use cases are provided in the user tutorial available as Supplemental Information.
In this example, we want to identify the most clinically relevant microsatellite instable cell lines that capture the genomic diversity of a sub-cohort of colorectal cancer patients that harbour BRAF mutations. BRAF mutant colorectal cancers have a low prevalence (5%-8%) and very poor prognosis (Sanz-Garcia et al., 2017) . In this example, the model selection will be performed accounting for somatic mutations that are prevalent in at least 5% of the considered colorectal patient cohort ( Figure 2A : box 1 and box 2).
Building the CELLector search space
After setting the CELLector app parameters to reflect the search criteria detailed in the previous section ( Figure 2A : box 1 and box 2), the CELLector search space is assembled using a built-in dataset containing the genomic characterisation of a cohort of 517 colorectal cancer tumours (Supplemental Information Table S1 and STAR Methods).
First, the cohort is reduced to the tumours harbouring BRAF mutations ( n=86 , Figure   2A : node 1). CELLector then identifies 3 major molecular subpopulations characterised, respectively, by APC mutations ( 
Selection of representative in vitro models
The CELLector search space generated as detailed in the previous section is next 
CELLector Bridges Cancer Patient Genomics with Cell Line Based Pharmacogenomic Studies
To fully demonstrate the potential of the CELLector analytical framework we performed two landmark analyses: (i) linking results and findings from large scale drug screens performed in vitro to cancer patient cohorts; (ii) performing a systematic estimation of the largest patient sub-cohorts currently lacking representative in vitro models across multiple cancer types (Figure 3 ). Executing these analyses routinely and on increasingly larger tumour datasets in the future might serve to (i) in-silico prescribe drugs to precisely defined sub-cohorts (segments) of cancer patients; (ii) prioritise in vitro models for future development.
Particularly, by making use of publicly available data , we applied
CELLector systematically to a large number of patient cohorts (STAR Methods) which were segmented into patient subtypes with associated combinations of the most prevalent genomic alterations, e.g patient-defined signatures across different cancer types ( Figure 3A ).
Then we mapped cell lines onto the identified patient segments based on the collective presence/absence of the corresponding signatures. In this way we generated a landscape of cancer patient sub-cohorts currently represented/non-represented by available in vitro models, which can be used as a rule-book for the generation of new cell lines and organoid models ( Figure 3B ), as well as a means to directly link cancer patient subpopulations to large cell line based pharmacogenomic studies ( Figure 3C ). In fact, the identified CELLector signatures that are present in a suitable number of cancer cell lines can be systematically correlated with drug responses observed in large scale cell line based screenings, thus providing a powerful and clinically relevant way to associate tumour genotypes (together with their prevalence) with established or potential cancer therapies. As we show in the following sections, this enables an in silico prescription of existing drugs directly to precisely defined subgroups of cancer patients, and might serve for the identification of complex and more robust markers of drug response ( Figure 3C ). This enables to assemble a landscape of tumour subtypes currently represented-by (orange)/lacking (grey) suitable in vitro models, which represents a valuable resource to prioritize the generation of new in vitro models across different cancer types. C. The patient-defined signatures can then be used as possible predictors of differential drug sensitivity in cancer cell lines providing an estimation of potential clinical relevance and size of the patient cohort that would respond to the therapy. This framework provides a means for in silico prescribing drugs to precisely defined subpopulation of cancer patients.
Landscape of tumour subtypes currently represented-by/lacking suitable in vitro models
To estimate the genomic heterogeneity of primary tumours and to assemble a landscape of patient subtypes currently represented-by/lacking suitable in vitro models, we systematically applied CELLector to large cohorts of primary tumours across 22 cancer types, focusing on cancer driver somatic mutations (SMs), copy number alterations (CNAs) and combination of both SMs and CNAs, occurring in at least 2% of a patient cohort ( Figure   4A , Supplementary Figure S1 , Supplementary Data S1). This analysis identified a total number of 718 patient-defined signatures (and corresponding patient segments) and highlighted that 46.8% (n=336) of them are covered by at least one tissue-matched cell line in the Cell Model Passport collection (a widely representative collection of in vitro models) (van der Meer et al., 2019) . Strikingly, the remaining 53.2% (n=382) of identified patient segments (signatures) lack representative in vitro models ( Figure 4B , Supplementary Figure   S2 , Supplementary Data S1).
Collectively, the tumour subtypes defined by the signatures and covered by at least one tissue-matched model spanned across 56% of patients with available data when considering either signatures of mutations or copy number alterations (74% when considering both); 35% and 32% (respectively for mutations, and copy number alterations, 14% when considering both) of patients were not included in any of the CELLector defined sub-cohorts, indicating that their genomes only host rare mutations/CNAs (frequency < 2% of their cohort). Finally, 8% and 12% (respectively for mutations, and copy number alterations, 11% when considering both) of patients fall into at least one recurrent subtype (covering > 2% of patients) strikingly lacking representative in vitro models (Supplementary Figure S3A) . Among the most underrepresented cancer types we found brain lower grade glioma (LGG; 95.1% of patients falling into at least one subgroup lacking representative in vitro models), followed by prostate adenocarcinoma (PRAD; 62.16% of patients) (Supplementary Figure S1 ).
This analysis also highlighted large disease subtypes that should be taken in consideration while prioritizing new in vitro models for future development ( Figure 4C ). As an example, despite the large availability of LGG cell lines (when compared to other cancer types), none of these harbour IDH1 mutations, which define the largest LGG patients Figure 4C ). have a discriminative prognostic power in colorectal tumour stratification (Schell et al., 2016) .
As another example, the genomic landscape of mutually exclusive BRAF -and NRASmutant melanomas detected by CELLector when performing a SKCM specific analysis with default parameters can be further contextualized, providing insights into co-occurring mutations and copy number alterations (Hodis et al., 2012) .
To programmatically estimate the potential clinical relevance and translational potential of the CELLector signatures, we systematically correlated their status observed in the cell lines with their responses to 495 compounds using publicly available data from the GDSC project (Garnett et al., 2012; Iorio et al., 2016 . Furthermore, we also performed a systematic survival analysis using CELLector signatures and individual CFEs to define subpopulations of patients to be contrasted for differential prognosis using data from cBioPortal (Cerami et al., 2012) .
CELLector signatures are involved in novel robust pharmacogenomics interactions
We performed cancer-type specific Analyses of Variance ( Furthermore across all cancer types, we observed that for 88 unique drugs at least one significant drug-signature association ( p < 0.001) was more significant than the most significant drug-CFE association involving the same drug ( Figure 5B , Supplementary Figure   S5A , Supplementary Data S5), in at least one cancer-type specific ANOVA. This was observed invariantly across cancer types (with the exception of the PRAD specific analysis) with a median number of 4 drugs per cancer type ( Figure 5B , Supplementary Figure S5A ).
For several cases the difference in significance was conspicuously large and associated with an increased level of drug sensitivity ( Figure 5CD and Supplementary Figure   S5B ). For example, we found that increased sensitivity to the second mitochondrial-derived activator of caspases ( SMAC ) mimetic and inhibitor of IAP (Inhibitor of Apoptosis Protein)
LCL161 is weakly associated ( p = 1.6 x 10 -3 , FDR = 69% ) with gains of a genomic segment containing the MDS1 and EVI1 complex locus (MECOM) oncogene in OV cell lines (occurring in 25% of patients) . A signature occurring in 15% of cancer patients and accounting for amplifications of the same segment, in combination with TP53 mutations and copy-number wild-type MYC is associated with sensitivity to LCL161 much more significantly ( p = 2 x 10 -5 , FDR = 7.8% , Figure 5C ). Further, gains of three genomic segments of chromosome 8, containing the POU Class 5 Homeobox 1B (POU5F1B), the Adenylyl cyclase type 8 (ADCY8), and other genes, in combination with losses of CUB and Sushi
Multiple Domains 1 (CSMD1) -all occurring simultaneously in 18% of BRCA patients -was much more significantly associated with sensitivity to the MEK5/ERK5 inhibitor BIX02189 ( p = 8.3 x 10 -5 , FDR = 11% , Figure 5C ) than the top predictive individual CFE (hypermethylation of the glutathione S-transferase theta 1 -GSTT1 -gene promoter, p = 8.5 x 10 -4 , FDR = 29% , occurring in 17% of BRCA patients).
Notably, in many other cases, CFEs consisting of mutations or amplifications of canonical oncogenes associated with increased sensitivity to a given drug (often targeting their coded protein) with a lower significance than a drug-signature association involving the same CFEs in combination with secondary genomic alterations ( Figure 5D and Supplementary Figure S5B Figure 5D and Supplementary Figure S5B ). Nevertheless, increased sensitivity to these compounds was much more significantly associated with a signature composed of MYC amplifications in combination with CN wild-type segments containing, among other genes, the RNA Binding Fox-1 Homolog 1 (RBFOX1), the SMAD family member 4 (SMAD4) and the ElaC Ribonuclease Z 1 (ELAC1) -(max p = 5 x 10 -4 , FDR ranging in [11%, 45%], Figure 5D and Supplementary Figure S5B , FDR = 61% ) -observed in 40% of patients ( Figure 5E ). Overview of significant pharmacogenomic interactions (data points) across cancer types and types of involved features: respectively, individual cancer functional events (CFEs, on the first row) and CELLector signatures (with coordinates on the y-axis indicating the signature length, in terms of contained CFEs). Coordinate on the x-axis indicate the interaction significance. Point colors indicate cancer type specific analysis in which an interaction was detected as significant and triangular shapes indicate drug-signature interaction involving a drug with no significant drug-CFE interactions. B. P-value comparison for top significant drug-signature associations and drug-CFE associations for all screened drugs and across cancer types, as indicated by the different color. Each point represents a drug with coordinates on the two axis reflecting the significance level of the top significant associations. C. Pairs of plots with examples of drug-signature associations (second plot in each pair) that are much more significant than the top significant drug-CFE association involving the same drug (first plot in each pair). Each circle represents a cell line with coordinate on the y-axis indicating the log IC50 of the drug specified in the y-axis label. In each individual plot, cell lines are partitioned into two groups based on the status of a genomic feature (TRUE or FALSE, indicating respectively the presence or absence of that feature). These features can be individual CFEs (first plot in each pair) or CELLector signatures (second plot in each pair), and are specified in the Furthemore, our analyses unveiled potential novel multivariate markers able to define very precisely sub-cohorts of putative sensitive (resp. resistant) patients in the context of drugs with established resistance (resp. sensitivity) markers ( Figure 5F ). For example, in LUAD cell lines, our analyses confirmed (although weakly) the established association between TP53 mutations (observed in 49% of LUAD patients) and resistance to the inhibitor of the TP53-MDM2 interaction Nutlin-3a (Kojima et al., 2006) ( p = 1.4 x 10 -3 , FDR = 61% ).
At the same time, a much more significant associations ( p = 1.8 x 10 -4 , FDR = 20% ) between sensitivity to Nutlin-3a and a CELLector signatures describing a sub-cohort of LUAD patients (23%) with wild-type TP53 and hypermethylation of the ADP Ribosylation Factor Like GTPase 17A (ARL17A) gene promoter was unveiled ( Figure 5F ). Viceversa, a signature describing a sub-cohort of COREAD patients with mutations in APC, TP53, KRAS, and based on the absence of these two alterations and hypermethylation of the GSTT1 promoter (observed in 5% of the cohort) ( Figure 6A ).
Finally, to evaluate the potential clinical impact of the CELLector signatures, we quantified, across cancer types, to what extent considering drug-signature sensitivity associations in addition to drug-CFE sensitivity associations varies the number of patients whose cancer hosts at least one drug sensitivity marker, compared to considering CFE-drug associations only. To this aim we quantified the percentages of patients, across cancer types, harboring at least one feature significantly associated with increased drug response (p < 0.001, FDR < 25%, for at least one drug), with a feature being a CFE in the first case and a CFE or a CELLector signature in the second case.
Notably, the number of patients harbouring sensitivity markers increased when considering both CFEs and CELLector signatures, for 8 out of 12 cancer types ( Figure 6B , median = 4.88%, ranging from 24% for BLCA to 0% for THCA, STAD and LGG).
Specific sets of drugs explain these differences ( Figure 6C ( Figure 6C ).
CELLector signatures are associated with differential prognosis
To further assess the clinical relevance of the CELLector signatures, we performed a systematic differential survival analysis across cancer types using publicly available survival data from cBioPortal (Cerami et al., 2012) .
As for the drug association study presented in the previous section, comparing significance of top prognostic CELLector signatures with that of top prognostic individual CFEs showed that for STAD, LUAD and HNSC the former were more robustly associated with differential survival than the latters ( Figure 6D , and Supplementary Figure S5D ). These signatures describe two complementary sub-cohorts of the KRAS mutant LUAD patients and cell lines mapped by CELLectors onto these two sub-cohorts are much more significantly sensitive Dabrafenib and Selumetinib, respectively. Thus the two drugs could be prescribed in silico to these two distinct patient sub-cohorts. Pie-charts show KRAS mutation and CELLector signature prevalence in LUAD patients. In the plots, each circle represents a cell line with coordinate on the y-axis indicating the log IC50 of the drug specified in the y-axis label. Cell lines are partitioned into two groups based on the status of KRAS (TRUE or FALSE, indicating respectively the presence or absence of mutations) or the CELLector signatures (TRUE or FALSE depending on the logic formula described in the signature being satisfied or not). P-values and False Discovery Rates are from Analysis of Variance (ANOVA) tests assessing the extent of differential drug response across the considered dichotomies of cell lines. The boxes cover interquartile ranges with median lines drawn within them. Whiskers extend to a maximum of 1.5 times the size of the interquartile range. B. Percentages of patients harboring a sensitivity marker, either an individual Cancer Functional Event (CFE, brighter colour) or both CFEs and CELLector signatures (darker colour) for at least one of the screened drugs considered in our ANOVAs, across cancer types (as indicated by the different colours). C. Examples of drugs for which the percentages of patients harboring a sensitivity marker increases when considering signatures in addition to CFEs, across cancer types. D. Systematic comparison of differential survival Cox p-values (corrected by age and gender) for top predictive individual CFE and CELLector signatures across cancer types.
Discussion
The translational potential of cancer preclinical studies is highly dependent on the clinical relevance of the employed in vitro models. Good models are required to capture the genomic heterogeneity of a cancer type under investigation and/or accurately represent alterations in relevant biological pathways.
We presented CELLector, a tool that allows scientists to select the most representative set of cell line models, maximising the covered genomic heterogeneity of the disease under consideration. The overall aim of the CELLector algorithm is to globally assess the quality of cancer in vitro models in terms of their ability to represent recurrent genomic subtypes detected in matched primary tumours, and to make available to the research community a user-controlled environment to perform such a task.
A key strength of CELLector is its generality: the algorithm can be applied to any disease for which in vitro models and matching primary/model genomic data are available.
CELLector enables the systematic identification of recurrent tumour subtypes with paired genomic signatures, and selection of in vitro models based on the recurrence of these signatures. In addition, the algorithm identifies disease subtypes currently lacking representative models enabling prioritisation of new model development. To the best of our knowledge, CELLector represents the first computational method that ranks and selects cancer in vitro models, in a data driven way, across different cancer types, and without the need for expert knowledge about the primary disease under consideration. However, the model selection performed by CELLector can be flexibly tailored to fit the context of a study.
Here, we also demonstrated the power of CELLector analytical framework in bridging 
Supplementary Figures
Supplementary Figure S1 -Systematic evaluation of tumour genomic heterogeneity and identification of tumour subtypes represented-by/lacking-representative in vitro models. The genomic landscape of 14 cancer types estimated using CELLector based on somatic mutation, copy number alterations and combination of both somatic mutations and copy number alterations in at least 2% of patient cohort. In each sunburst, segments represent tumour subtypes with those in grey indicating tumour subtypes lacking representative in vitro models. Pie charts represent proportion of patients that are not accounted for in the sunburst (white), or are accounted but not represented by any existing in vitro model (grey), or belonging to a subtype for which there is at least a representative in vitro model (color-coded respectively to cancer type). Number of drugs included in each cancer type specific ANOVA (1st column), for which there is at least one CELLector signatures associated with differential drug response more significantly than the top significant (p < 0.001) individual cancer functional event (CFE) (2nd column), for which there is at least one CELLector signature but no individual CFEs significantly (p < 0.001) associated with differential drug response (3rd column). B. Pairs of plots with examples of drug-signature associations (second plot in each pair) that are much more significant than the top significant drug-CFE association involving the same drug (first plot in each pair). Each circle represents a cell line with coordinate on the y-axis indicating the log IC50 of the drug specified in the y-axis label. In each individual plot, cell lines are partitioned into two groups based on the status of a genomic feature (TRUE or FALSE, indicating respectively the presence or absence of that feature). These features can be individual CFEs (first plot in each pair) or CELLector signatures (second plot in each pair), and are specified in the 
Supplementary
Genomics data
CELLector provides built-in genomics data for disease-matched primary tumours and cell lines derived from 16 cancer types, encompassing the characterisation of 4,550 tumours and 499 immortalised and commercially available cancer cell lines (Supplemental Information   Table S1 ), and accounting for somatic mutations, copy number alterations and hypermethylated gene promoters for high-confidence cancer genes and recurrently altered chromosomal segments, i.e. cancer functional events (CFEs). These CFEs are described in Iorio et al. , 2016 and corresponding data were obtained from the accompanied web-portal ( http://www.cancerrxgene.org/gdsc1000/ ).
QUANTIFICATION AND STATISTICAL ANALYSIS: The CELLector algorithm
In the analytical framework of CELLector, the genomic background of a cohort of patients affected by a given cancer type is represented as a binary tree whose topology is determined by the most-frequently observed combinations of molecular alterations (item-sets) and their supports, i.e. the fraction of patients in which these alterations occur simultaneously. This tree is built recursively by sequential applications of the Eclat algorithm (Zaki et al., 1997) as follows. The tree construction starts from the root, modelling the combination of genomic alterations (item-set) with the largest support across the entire cohort. Then two sibling nodes are included, modelling the item-sets with the greatest support when considering the population supporting the item-set of the parent node (right sibling node) and its complementary population (left sibling node). This is recursively performed at each new node included in the tree if the corresponding modelled item-set is supported by at least a user-defined ratio of patients in the considered patient subpopulation (for example 5%).
Subsequently, a logic AND formula F is assigned to each node x , considering the path to x from the root of the three. For each node n on this path (including the terminal ones) the corresponding modelled item-set is added to F as a term, negated if n is a left sibling (complement) node. Finally, a given cell line in the built-in collection is mapped to a node n if its genomic background satisfies F(n).
The algorithm continues with a guided deep-first-visit of the obtained tree, which return all the identified subtypes as a sorted list, as detailed in the following pseudo code: Detailed instructions on how to install the R package, run the CELLector analysis and interactively explore the results are also provided in the GitHub repository and in the were performed. Each ANOVA was performed using the analytical framework implemented in the GDSCtools Python package (Cokelaer et al., 2018) were not included in this analysis due to asymmetric patient identifiers. The obtained patient-defined signatures and individual Cancer Functional Events (CFEs, from ) were collated into one feature matrice per cancer type (Supplementary Data S6) and used in systematic differential survival analysis. In cases where patient-defined signatures were duplicated (e.g. the same signature was present in multiple CELLector analyses or signature and CFE were the same), the prevalence of that signature in the studied patient cohorts was considered; the duplicate with higher number of underlining patients was retained. The clinical data for systematic survival analysis were downloaded from cBioPortal
Supplemental Information
Supplemental Information includes one table, two case studies, instructions how to install and run different CELLector modalities (e.g. R package, online and local R Shiny App) and user tutorials demonstrating the full functionality of CELLector app.
